Directing systemic oncolytic viral delivery to tumors via carrier cells |
| |
| Authors: | Hiroshi Nakashima Balveen Kaur E.A. Chiocca |
| |
| Affiliation: | 1. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;2. The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;3. Department of Bioengineering, Rice University, Houston, Texas, USA;4. Department of Neurosurgery, Juntendo University School of Medicine, Tokyo, Japan;5. Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA |
| |
| Abstract: | ![]()
The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the virus by host defense mechanism and spurious targeting of non-cancer tissues through the bloodstream. Cell mediated OV delivery could hide the virus from host defenses and direct them toward tumors: Mesencymal and neural stem cells have been described to possess tumor-homing ability as well as the capacity to deliver OVs. In this review, we will focus on approaches where OV and carrier cells are utilized for cancer therapy. Effective cellular internalization and replication of OVs need to occur both in cancer and carrier cells. We thus will discuss the current challenges faced by the use of OV delivery via carrier cells. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
